Sarah Burgin, MD
Otolaryngology · Indianapolis, INNPI 1639498272
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,410 of the $3,686 with a category attached, or 65.4%. Smith+Nephew accounts for 83.4% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $3,380, more than ten times the $83 reported in 2019.
Across 36 payments — averaging $102.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$3K
- Kls-martin L.p.$169
- GSK$125
- Regeneron Healthcare Solutions, Inc.$123
- Integra Lifesciences Corporation$62
- Cochlear Americas$46
- plus $86 from 4 others
What the payments were for
- Travel & lodging$2,41065%
- Food & beverage$1,27635%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 13 | $3,076 |
| Kls-martin L.p. | 2 | $169 |
| GSK | 8 | $125 |
| Regeneron Healthcare Solutions, Inc. | 4 | $123 |
| Integra Lifesciences Corporation | 3 | $62 |
| Cochlear Americas | 2 | $46 |
| Inspire Medical Systems, Inc. | 1 | $33 |
| Aerin Medical Inc. | 1 | $22 |
| Stryker | 1 | $16 |
| Convatec Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,686 in reported general payments places this provider in the 75th percentile of 193 otolaryngology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mometasone Furoate | 13 | $1,183 |
| Ventolin HfaAlbuterol Sulfate | 12 | $647 |
| Azelastine Hcl | 23 | $597 |
| Fluticasone Propionate | 45 | $502 |
| Prednisolone Acetate | 12 | $356 |
| Ofloxacin | 22 | $311 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 28 | $175 |
| Montelukast Sodium | 19 | $160 |
| Famotidine | 21 | $148 |
| Prednisone | 16 | $57 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $44 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Indianapolis
- Satyan SreenathIndianapolis$103K
- Elisa IllingIndianapolis$28K
- Benjamin CopelandIndianapolis$9K
- Daniel VinhIndianapolis$9K
- Avinash MantravadiIndianapolis$4K
- Jason GuttIndianapolis$4K
- Richard BiggerstaffIndianapolis$3K
- Anthony FamaIndianapolis$3K
- David FangIndianapolis$3K
- Jonathan TingIndianapolis$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.